AmorChem supports orphan drug development

Guest Contributor
September 26, 2013

Montreal-based venture capital fund AmorChem LP is investing in the research of Dr Pascal Chartrand to develop a therapeutic treatment for myotonic dystrophy, a rare hereditary disease for which there is no current cure. AmorChem will provide an undisclosed amount of funding to Univalor, the technology transfer and commercialization arm of the Univ of Montreal, its affiliated schools and hospitals. The work will be conducted by NuChem Therapeutics, which is a medicinal chemistry contract research subsidiary of AmorChem — the latest addition to the GeneChem portfolio of funds. Its limited partners are Investissement Québec, FIER Partenaires, Fonds de solidarité FTQ and Merck & Co. Chartrand is a researcher with the Institut de recherches cliniques de Montréal, which employs 425 people and is an independent institution affiliated with the U of M….

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.